Dr David Yeo is an Upper GI Surgeon based in Sydney, NSW. As well as upper gastrointestinal surgery Dr Yeo specialises in hepatobiliary surgery (liver, pancreas, gallbladder and bile duct), transplant and bariatric surgery. He has a broad special interest and expertise in cancerous and non – cancerous conditions including liver tumours, biliary/gallbladder and pancreatic tumours. He also offers a full range of surgical treatments including laparoscopic (keyhole) surgery for gallstones, hernias, and bariatric/obesity surgery as well as endoscopy and ERCPs.

Dr David Yeo completed a Bachelor of Medical Science degree at the University of Sydney and went on to study Medicine graduating in 2002 with Honours. He undertook surgical training at both the RPA and St George Hospitals obtaining his General Surgical Fellowship in 2009. David then spent the next two years of his post-fellowship training completing the Australian and New Zealand Hepato-Pancreato-Biliary Association Fellowship program based at RPA Hospital in Sydney and the Austin Hospital in Melbourne. In his fourth and final post-fellowship year he travelled to the United Kingdom to work at St James¹s University Hospital where he gained expertise in aggressive oncological liver resection and liver transplantation.

​Academically, David completed a Master of Surgery in 2008 focusing on the impact of PET/CT imaging on the treatment of colorectal cancer liver metastases. He is the Clinical Research lead in Upper Gastrointestinal Surgery within the Institute of Academic Surgery at RPA Hospital.

David has broad clinical interests. Oncologically, he specialises in both primary and secondary liver tumours, stomach, pancreatic and biliary/gallbladder tumours. He performs an extensive range of non-cancer related operations for conditions such as gallstone disease, hernias and obesity. In addition, he is involved with medical device development aiming to improve the safety and effectiveness of current technologies. He was awarded a grant from the NSW government following completion of the ATP Innovation Medical Device Commercialisation Training Program.